Skip to main content

Table 1 Dietary supplement use of the study population and according to cancer sites of cancer survivorsa

From: Dietary supplement use among cancer survivors and the general population: a nation-wide cross-sectional study

 

All

Female

Male

Number

Dietary supplement use % (SE)

Number

Dietary supplement use % (SE)

Number

Dietary supplement use % (SE)

Cancer-free individuals

10,387

22.1 (0.6)

6154

26.0 (0.7)

4233

18.1 (0.8)

Cancer survivors

400

33.3 (2.8)

260

37.0 (3.6)

140

26.7 (4.7)

P valueb

< 0.001

0.001

0.04

By cancer site

Stomach

71

29.8 (6.1)

27

38.3 (11.4)

44

23.9 (7.0)

Cervix or corpus uteri

67

38.1 (7.2)

67

38.1 (7.2)

0

–

Thyroid

63

31.7 (6.5)

54

31.7 (7.1)

9

31.6 (16.3)

Breast

59

55.9 (7.0)

59

55.9 (7.0)

0

–

Colorectal

52

22.5 (5.9)

27

18.5 (8.1)

25

26.6 (8.6)

Bladder

14

28.7 (4.0)

5

23.1 (0.0)

9

31.5 (5.9)

Lung

13

23.0 (11.4)

4

49.6 (28.3)

9

15.7 (5.4)

Prostate

12

19.4 (7.0)

0

–

12

19.4 (7.0)

Liver

11

25.8 (6.4)

2

0.0

9

28.5 (7.1)

Renal

9

0.0

4

0.0

5

0.0

Othersc

46

29.2 (6.0)

20

25.1 (12.7)

26

32.0 (8.4)

  1. aCancer survivors with multiple cancer sites were counted multiple times; 11 participants had been diagnosed with cancer at two sites, and 3 participants had been diagnosed with cancer at three sites among the 400 cancer survivors
  2. bRao-Scott chi-square p values were obtained using PROC SURVEYFREQ to compare the proportion of dietary supplement use between cancer survivors and cancer-free individuals
  3. cOthers included 19 cancer sites (e.g., larynx, lymphoma, skin, ovarian, and esophageal)